v3.25.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule of operating results of company’s segment

The following table presents the operating results of the Company’s segment:

 

  2025   2024   2025   2024 
   Three Months Ended June 30,   Six Months Ended June 30, 
  2025   2024   2025   2024 
Operating expenses:                    
Research and development                    
Clinical operations  $763,860   $65,966   $1,871,334   $1,143,156 
Drug manufacturing and formulation   1,110,084    1,462,519    1,490,437    1,803,718 
Personnel   409,220    343,762    970,554    649,714 
Regulatory   417,775    8,846    591,240    91,490 
Total research and development   2,700,939    1,881,093    4,923,565    3,688,078 
General and administrative                    
Personnel   459,336    404,586    1,030,866    817,863 
Legal and professional fees   968,987    494,468    1,474,487    810,153 
Occupancy   88,359    73,846    149,986    174,533 
Insurance   174,449    241,524    370,045    483,048 
Other   257,904    110,663    407,060    180,722 
Total general and administrative   1,949,035    1,325,087    3,432,444    2,466,319 
Operating loss   (4,649,974)   (3,206,180)   (8,356,009)   (6,154,397)
Interest and other income (expense), net   (138,761)   (3,497)   (235,417)   (27,757)
Loss before income taxes   (4,788,735)   (3,209,677)   (8,591,426)   (6,182,154)
Income tax benefit (expense)   -    -    -    - 
                     
Net loss and comprehensive loss  $(4,788,735)  $(3,209,677)  $(8,591,426)  $(6,182,154)